Inebilizumab: Anti-CD19 MAb, treatment of neuromyelitis optica, treatment of relapsing-remitting multiple sclerosis, treatment of B-cell malignancies
-
Published:2016
Issue:1
Volume:41
Page:9
-
ISSN:0377-8282
-
Container-title:Drugs of the Future
-
language:en
-
Short-container-title:Drugs Fut
Publisher
Clarivate Analytics (US)
Subject
Pharmacology (medical),Pharmacology